Target intelligence / Profile preview

SLC18A2 antisense RNA 1 (SLC18A2-AS1)

Target
SLC18A2-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA
01

Overview

SLC18A2 antisense RNA 1 (SLC18A2-AS1) is a long non-coding RNA gene located antisense to the SLC18A2 gene, which encodes the vesicular monoamine transporter 2 (VMAT2)[4][6]. Antisense RNAs typically function to regulate the expression of their corresponding sense gene or neighboring loci by mechanisms involving transcriptional interference, chromatin remodeling, or RNA stability[2]. While SLC18A2 itself is a well-established transporter involved in monoamine neurotransmitter handling and implicated in various neuropsychiatric conditions[1][3][5], current data on SLC18A2-AS1 are limited, with its precise biological and disease roles still unclear. It is categorized as a non-coding RNA and is not itself a therapeutic target, receptor, or enzyme.\n\nIf more specificity about its disease involvement or regulation becomes known, or if a therapeutic targeting approach is developed, those attributes may be updated. Currently, most knowledge applies generally to antisense lncRNAs as a class.

Other names
SLC18A2-AS1
02

Mechanism of action

Gene expression modulation via antisense regulation mechanisms (transcriptional interference, chromatin modification, transcript stability)

03

Biological functions

Regulation of gene expressionEpigenetic regulation (via cis- and/or trans-acting mechanisms)
04

Disease associations

Potential roles in cancer (generic to many antisense RNAs)regulation of neurological and psychiatric disease pathways through modulation of SLC18A2, but no specific established disease association unique to SLC18A2-AS1 in current literature
05

Safety considerations

Antisense RNAs as a class may present challenges for specificity and off-target effects in therapeutic contexts but no specific safety concerns established for SLC18A2-AS1

Beyond the preview

Go deeper on SLC18A2 antisense RNA 1 (SLC18A2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLC18A2 antisense RNA 1 (SLC18A2-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call